Definium Therapeutics, Inc. Total Assets
Definium Therapeutics, Inc. total assets. Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) holds total assets worth $1.11 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Definium Therapeutics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Definium Therapeutics, Inc. (2015–2025)
Total assets of Definium Therapeutics, Inc. from 2015 to 2025. This chart illustrates how Definium Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Definium Therapeutics, Inc. for real-time trading data and today's change.
Definium Therapeutics, Inc. - Asset Composition Analysis
Definium Therapeutics, Inc. Total Assets Breakdown (December 2025)
Definium Therapeutics, Inc. total assets breakdown as of December 2025. Definium Therapeutics, Inc.'s total assets of $1.11 Billion consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $19.92 Million | 4.5% |
Asset Composition Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore DFTX current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Definium Therapeutics, Inc.'s current assets represent 95.3% of total assets in 2025, an increase from 63.9% in 2015.
- Cash Position: Cash and equivalents constituted 58.6% of total assets in 2025, up from 1.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 4.5% of total assets.
Definium Therapeutics, Inc. Competitors by Total Assets
Key competitors of Definium Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Definium Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.95 | 4.98 | 25.32 |
| Quick Ratio | 6.95 | 4.98 | 25.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $934.90 Million | $151.18 Million | $140.72 Million |
Definium Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Definium Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.52 |
| Latest Market Cap to Assets Ratio | 10.20 |
| Asset Growth Rate (YoY) | 45.7% |
| Total Assets | $440.10 Million |
| Market Capitalization | $4.49 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Definium Therapeutics, Inc.'s assets at a significant premium (10.20x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Definium Therapeutics, Inc.'s assets grew by 45.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual total assets of Definium Therapeutics, Inc. from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $440.10 Million | +45.66% |
| 2024-12-31 | $302.15 Million | +142.61% |
| 2023-12-31 | $124.54 Million | -26.74% |
| 2022-12-31 | $169.99 Million | +3.65% |
| 2021-12-31 | $164.00 Million | +101.18% |
| 2020-12-31 | $81.52 Million | +2675.66% |
| 2019-12-31 | $2.94 Million | -16.87% |
| 2018-12-31 | $3.53 Million | -12.28% |
| 2017-12-31 | $4.03 Million | +1886.43% |
| 2016-12-31 | $202.75K | -30.48% |
| 2015-12-31 | $291.66K | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more